Cara Therapeutics Inc (CARA)
0.3065
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 14:44
Cara Therapeutics Enterprise Value: -25.03M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -25.03M |
| November 20, 2024 | -25.31M |
| November 19, 2024 | -25.53M |
| November 18, 2024 | -25.99M |
| November 15, 2024 | -24.97M |
| November 14, 2024 | -24.07M |
| November 13, 2024 | -24.26M |
| November 12, 2024 | -23.33M |
| November 11, 2024 | -23.33M |
| November 08, 2024 | -23.39M |
| November 07, 2024 | -23.11M |
| November 06, 2024 | -24.96M |
| November 05, 2024 | -26.08M |
| November 04, 2024 | -26.03M |
| November 01, 2024 | -25.75M |
| October 31, 2024 | -25.01M |
| October 30, 2024 | -26.19M |
| October 29, 2024 | -27.40M |
| October 28, 2024 | -27.23M |
| October 25, 2024 | -27.34M |
| October 24, 2024 | -28.09M |
| October 23, 2024 | -27.45M |
| October 22, 2024 | -27.28M |
| October 21, 2024 | -27.47M |
| October 18, 2024 | -27.50M |
| Date | Value |
|---|---|
| October 17, 2024 | -27.40M |
| October 16, 2024 | -27.50M |
| October 15, 2024 | -28.05M |
| October 14, 2024 | -27.99M |
| October 11, 2024 | -28.29M |
| October 10, 2024 | -28.12M |
| October 09, 2024 | -27.79M |
| October 08, 2024 | -27.99M |
| October 07, 2024 | -27.44M |
| October 04, 2024 | -26.92M |
| October 03, 2024 | -26.90M |
| October 02, 2024 | -26.14M |
| October 01, 2024 | -26.30M |
| September 30, 2024 | -25.14M |
| September 27, 2024 | -39.89M |
| September 26, 2024 | -40.83M |
| September 25, 2024 | -41.39M |
| September 24, 2024 | -41.28M |
| September 23, 2024 | -40.11M |
| September 20, 2024 | -40.05M |
| September 19, 2024 | -39.69M |
| September 18, 2024 | -40.93M |
| September 17, 2024 | -41.97M |
| September 16, 2024 | -41.90M |
| September 13, 2024 | -42.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-72.42M
Minimum
Feb 08 2024
1.289B
Maximum
Apr 09 2021
358.64M
Average
436.53M
Median
Nov 29 2022
Enterprise Value Benchmarks
| Agilent Technologies Inc | 39.10B |
| Seelos Therapeutics Inc | 10.03M |
| Citius Pharmaceuticals Inc | 12.53M |
| Moleculin Biotech Inc | -0.9096M |
| NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.48M |
| Revenue (Quarterly) | 2.556M |
| Total Expenses (Quarterly) | 7.837M |
| EPS Diluted (Quarterly) | -0.23 |
| Profit Margin (Quarterly) | -488.1% |
| Earnings Yield | -571.0% |
| Normalized Earnings Yield | -496.65 |